Creso Pharma Limited
Melodiol Global Health Limited engages in the development, cultivation, and distribution of recreational and medical cannabis products in Europe, Canada, Australia, and the Asia Pacific. It is involved in the development and commercialisation of nutraceutical products; and medical supplies business. The company was formerly known as Creso Pharma Limited and changed its name to Melodiol Global Hea… Read more
Creso Pharma Limited (COPHF) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2023: 0.556x
Based on the latest financial reports, Creso Pharma Limited (COPHF) has a cash flow conversion efficiency ratio of 0.556x as of December 2023.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.26 Million) by net assets ($-4.06 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Creso Pharma Limited - Cash Flow Conversion Efficiency Trend (2015–2023)
This chart illustrates how Creso Pharma Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Creso Pharma Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Creso Pharma Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
WI Co. Ltd.
KQ:073570
|
-0.030x |
|
Spartoo SAS
PA:ALSPT
|
-0.027x |
|
Emico Holdings Bhd
KLSE:9091
|
0.123x |
|
TCI Finance Limited
NSE:TCIFINANCE
|
0.009x |
|
Canada Rare Earth Corp
PINK:RAREF
|
0.051x |
|
General de Galerias Comerciales SOCIMI S.A.
MC:GGC
|
0.190x |
|
Izolacja Jarocin SA
WAR:IZO
|
-0.020x |
|
EFXB31
SA:EFXB31
|
N/A |
Annual Cash Flow Conversion Efficiency for Creso Pharma Limited (2015–2023)
The table below shows the annual cash flow conversion efficiency of Creso Pharma Limited from 2015 to 2023.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2023-12-31 | $-4.06 Million | $-8.14 Million | 2.006x | +245.06% |
| 2022-12-31 | $22.29 Million | $-30.83 Million | -1.383x | -71.56% |
| 2021-12-31 | $27.76 Million | $-22.38 Million | -0.806x | -14.39% |
| 2020-12-31 | $13.65 Million | $-9.62 Million | -0.705x | -19.74% |
| 2019-12-31 | $17.27 Million | $-10.17 Million | -0.589x | -19.91% |
| 2018-12-31 | $16.50 Million | $-8.10 Million | -0.491x | -36.92% |
| 2017-12-31 | $21.03 Million | $-7.54 Million | -0.358x | +54.72% |
| 2016-12-31 | $3.24 Million | $-2.57 Million | -0.792x | -100.33% |
| 2015-12-31 | $-10.77K | $-2.57 Million | 238.151x | -- |